Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The ARCADIAN trial has received OCTRU Green Light approval and has now begun to open sites to recruitment!

Arcadian Trial Logo


A Phase I Trial of the Hypoxia Modifier Atovaquone in Combination with Radical Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer



ARCADIAN: Atovaquone with Radical ChemorADIotherapy in locally Advanced NSCLC


The ARCADIAN trial has received Green Light approval from OCTRU and subsequently opened to recruitment at its first site in Oxford.

Funded by CRUK, ARCADIAN aims to investigate whether the drug atovaquone can be safely given to patients undergoing chemoradiotherapy for Non-Small Cell Lung Cancer (NSCLC).

Atovaquone has previously been shown to reduce tumour hypoxia, a state which can cause resistance to traditional cancer treatments. If the study shows that it is safe to administer atovaquone with chemoradiotherapy, further studies would be planned to assess the efficacy of this combination treatment.


Find out more on the Department of Oncology website: